Nuvation Bio Inc. (NUVB), a biopharmaceutical company focused on addressing unmet needs in oncology, on Monday announced that the FDA has accepted its New Drug Application for Taletrectinib.
Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com